Zhejiang Medicine Co Ltd

China

Biotin

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

01

Biotin

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Daptomycin

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

02

Daptomycin

China

Iran Expo

Not Confirmed

Daptomycin

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Icosapent Ethyl

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

03

Icosapent Ethyl

China

Iran Expo

Not Confirmed

Icosapent Ethyl

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Levofloxacin

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

04

Levofloxacin

China

Iran Expo

Not Confirmed

Levofloxacin

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Linezolid

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

05

Linezolid

China

Iran Expo

Not Confirmed

Linezolid

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Miglitol

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

06

Miglitol

China

Iran Expo

Not Confirmed

Miglitol

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Minocycline Hydrochloride

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

07

Minocycline Hydrochloride

China

Iran Expo

Not Confirmed

Minocycline Hydrochloride

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Rifampicin

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

08

Rifampicin

China

Iran Expo

Not Confirmed

Rifampicin

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Rifaximin

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

09

Rifaximin

China

Iran Expo

Not Confirmed

Rifaximin

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Zhejiang Medicine Co Ltd

China

Sitagliptin Phosphate

Product
Web Link

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

About the Company

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Ex...
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

10

Sitagliptin Phosphate

China

Iran Expo

Not Confirmed

Sitagliptin Phosphate

China

Iran Expo

Not Confirmed

China

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.

About the Company : Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Co...

" class="fa fa-info-circle aboutFaIocn allDocuments about-content-lines-icon" aria-hidden="true">

Product
Web Link